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INTRODUCTION 
“Cerebrovascular Disease” or “Stroke” is one of the leading 
causes of mortality and morbidity in adult worldwide, posing serious 
medical, socio-economic and rehabilitation problems.  
Stroke, also called ‘Brain Attack’ because it involves an acute 
insult to the brain, is a major disabling disease.  
Hence, there is growing interest in unifying mechanisms in 
ischemic stroke pathogenesis. But, one half of the cerebrovascular 
disease risk could not be explained by conventional risk factors. 
 In  the  presence of atherosclerosis have to search for new stroke 
risk factors and treatment. 
The inflammatory like C-reactive protein, intercellular adhesion 
molecule-1, lipoprotein associated phospholipase A2, increased WBC 
count, Chlamydia pneumoniae, Helicobacter pylori and 
Cytomegalovirus; Homocysteine;  Renin angiotensin  system;  Tissue  
factor;  Fibrinogen;  Lipoprotein  (a);  Small  dense  LDL; etc., have 
been proposed as new risk factors for stroke.
4  One more addition to the 
growing list is ‘Microalbuminuria’ 
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Microalbuminuria has been associated with many disease 
entities like diabetic nephropathy, hypertension with left ventricular 
hypertrophy and renal insufficiency, etc. 
But, there was little information regarding microalbuminuria as 
an independent risk factor for stroke or as a predictor of stroke 
outcome. 
With the availability of sensitive and relatively inexpensive 
methods for detection of microalbuminuria, many studies were 
conducted in different parts of the world to determine the potential use 
microalbuminuria, as a marker of stroke risk and outcome in non-
diabetic population. 
Microalbuminuria is a marker for kidney disease and endothelial 
dysfunction, may be associated with global vascular risk. 
Microalbuminuria is a marker of abnormal vascular permeability 
and its presence considered as kidney notice for increasing 
cerebrovascular risk. 
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It is considered as an indicator of increased mortality in DM, 
SHT, acute MI. 
It is an independent risk factor for stroke or as a predictor of 
stroke outcome. 
Microalbuminuria may be a marker for early development of 
atherosclerosis  and a possible linkage between microalbuminuria and 
atherothrombotic stroke mechanisms. 
DEFINITION : 
Microalbuminuria is urinary excretion of albumin in the rate of  
30-300mg/day or an albumin creatinine ratio of 2.5-25 mg/mmol in 
males and 3.5-25mg/mmol in females. 
Study included all patients admitted in CMCH diagnosed with 
first  Ischemic stroke which is confirmed by CT scan brain within first 
24 hours of  onset of symptoms  
The severity of neurological deficit was measured by 
Scandinavian Stroke Scale on the day of  admission. 
The urinary albumin excretion was measured by using spot urine 
collection and by Micral test.  
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The patients were re-examined  after 6 weeks for activities of 
daily living using Barthel Index. 
Measuring microalbuminuria seems to be a reliable indicator of 
stroke outcome after 6 weeks of the stroke attack.  
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AIMS AND OBJECTIVES 
• To estimate the presence of microalbuminuria in non-diabetic 
recent ischemic stroke patients. 
• To evaluate the prognostic significance of microalbuminuria in 
these non-diabetic recent ischemic stroke patients. 
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REVIEW OF LITERATURE 
ISCHAEMIC STROKE DEFINITION 
Stroke 
WHO defines stroke as “the rapidly developing clinical symptoms 
and/or signs of local [at times global] disturbance of cerebral functions, 
with symptoms lasting for more than 24 hours or leading to death 
with no apparent cause other than that of vascular origin” [Hatano, 
1976].
5
 
Transient Ischaemic Attack (TIA) 
TIA, per se, does not impose any lasting burden on the individual 
or the society. 
 But it serves as a ‘warning signal’ for later occurrence of stroke 
and thus, may form the basis of a ‘high risk’ prevention strategy. 
Reversible Ischaemic Neurological Deficit [RIND] 
RIND defines an event characterized by neurological deficits that 
lasts more than one day but disappears within 7 days. 
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Stroke in Evolution 
It describes a progressive neurological deficit developing over 
a few hours or days, which evolves to completed stroke after a few 
hours or days. 
Completed Stroke 
It is the term applied to the temporal profile of the stroke 
syndrome in which the deficit is prolonged and often permanent causing 
demonstrable parenchymal changes. 
Small Vessel Stroke 
It is the infarction following atherothrombotic or lipohyalinotic 
occlusion of a small artery [30 - 300 mcm] in the brain [lacunar 
infarction]. 
CAUSES OF ISCHEMIC STROKE 
1. Thrombosis (a locally formed blood clot which obstructing the 
blood vessel ) 
2. Embolism  
3. Systemic hypoperfusion 
4. Venous thrombosis 
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Figure-1 
Image of Hemorrhagic and Ischemic Stroke 
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CLASIFICATION; 
Hachinske and Norris Classification 
Presumed Stroke  Presumed TIA 
Anatomic classification: 
a) By vascular supply   -               Carotid. 
                                                            Vertebrobasilar. 
b) By location 
Supratentorial -    lobar. Ganglionic / Thalamic. 
            Infratentorial -     Cerebellar. Brainstem.                                                         
Etiologic classification: 
a. By result 
• Cerebral Infarct     -            Arterial. 
                                                           Arteriolar.  
                                           Venous. 
• Cerebral hemorrhage  -     Parenchymal                   
                                                          Subarachnoid. 
A. Management classification: 
•  TIA and minor stroke. 
10  
• Major stroke. 
• Deteriorating stroke. 
• Young stroke.    
By cause 
Ischaemia - Embolism. 
- Extra cranial vascular disease. 
Hemorrhage - Hypertension.                                                                        
Amyloid Angiopathy.      
Vascular malformation.          
Aneurysm 
Oxfordsire stroke sub classification; 
a. Total anterior circulation syndrome 
b. Partial anterior circulation syndrome 
c. Lacunar syndrome 
d. Posterior circulation syndrome 
11  
Figure-2  
Cortical vascular teritory 
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Figure-3 
Blood Supply of the Brain  
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Figure-4 
Circle of Willis 
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FACTORS FAVOURING BLOOD SUPPLY TO THE ISCHEMIC 
BRAIN TISSUE 
Collateral circulation; 
          It helps to improve the affected area of brain.so, if colletral 
circulation is good, outcome will be better. 
Systemic circulation;  
 The blood pressure in the systemic circulation is an important 
factor to maintain cerebral perfusion pressure and cerebral auto 
regulation.  
 Systemic hypotension can result in global cerebral ischemia. 
FACTORS UNFAVOUR THE OUTCOME OF ISCHEMIC 
STROKE 
1. HYPER COAGULABLE STATE 
2. HYPERTHERMIA 
3. HYPERGLYCEMIA 
4. HYPOGLYCEMIA 
5. HYPOTENSION 
6. HEMORRHAGIC TRANSFORMATION 
15  
CEREBRAL BLOOD FLOW   
• Normal cerebral blood flow-60ml/100g/min 
• The cerebral auto regulatory mechanism maintains cerebral 
blood flow. 
• It maintains systemic circulation in the range of 60-150mmHg 
• CBF reduction during ischemia results in local vasodilatation 
and opening of collaterals 
• Irreversible neuronal injury occurs in CBF, of <10ml/100gm of 
tissue/min 
 ISCHEMIC PENUMBRA 
  The ischemic area is surrounded by an area of decreased  
perfusion. This area is called as the ischemic penumbra where auto 
regulation is in effective. 
WINDOW OF OPPORTUNITY 
     The   critical time period in which area of brain tissue is at risk is 
called  window of opportunity. The neurological deficits partly or 
completely  reversed, if reperfusion of the ischemic tissue is achieved in 
within this period.  
16  
NEURONAL DEATH 
 Death of neurons after injury takes places by two processes  
1. coagulation necrosis  
2. apoptosis 
Coagulation necrosis; 
 Cell death without inflammatory response in the surrounding cells 
is called as coagulation necrosis 
Apoptosis; 
          Programmed  cell death due to ischemia is called as apoptosis. 
Activation of silent suicidal proteins in the nucleoli, causes autolytic 
process and cell death. 
INTRACRANIAL HEMORRHAGE 
 Accumulation of blood within skull vault is called ICH 
 Intra axial- blood inside the brain, extra axial hemorrhage- blood 
inside the skull vault but out side the brain. 
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Extra axial hemorrhage 
1. Epidural 
2. Subdural 
3. subarachnoid 
EPIDEMIOLOGY 
Worldwide annual incidence of stroke is 0.2-2.5/1000 population. 
Worldwide prevalence rate of stroke is 500-600/1,00,000 population. 
About 15 million people affected by CVA every year worldwide. 
About one third of  CVA patients ends in permanent disability. 
About one third of CVA patient die. 
In Europe the stroke incidence is high in men than women. Indian 
stroke morbidity and mortality study shows in Dalal 2007 study 
prevalence is 55.6/100000 in all age group. 
WHO study shows 0.63 million death due to stroke in 2005. 
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A. Incidence and prevalence of stroke in India 
The first study were conducted in vellore. In the first phase (1968-
69), a population of 2,58,576 in and around Vellore was surveyed to 
detect the prevalent cases of stroke. The main observations made 
during this study are: 
1. Two year prevalence rate of stroke - 84 per 1,00,000 
population. 
2. Annual incidence of stroke  - 13 per 1,00,000 population. 
The second study was carried out as a part of WHO collaborative 
study in Rohtak, Haryana between 1971 and 1974.  The study made the 
following observations: 
1. Crude prevalence rate - 44 per 1,00,000 population. 
2. Annual incidence of Stroke - 33 per 1,00,000 population. 
Subsequent study done in Gowribidanur in Karnataka in South 
India found the prevalence rate of stroke to be 52/1,00,000. 
In Eastern India, a neuroepidemiological study in rural Bengal 
found prevalence of stroke to be 126/1,00,000 and in Chottanagapur in 
Bihar it was 103/100,000. 
19  
The stroke prevalence in Metropolitan city of Mumbai has been 
reported as high as 245/100,000. 
In a smaller study in New Delhi, the crude prevalence of stroke 
has been reported to be 125/100,000 population. 
Mortality due to stroke 
The stroke mortality rate is 73 per 100,000. 
EPIDEMIOLGY OF MICROALBUMINURIA 
Microalbuminuria is defined as levels of albumin between 30 - 
300 mg per day (equivalent to 20 to 200 µg/minute in a timed overnight 
urine collection, 20-200 mg/L on spot urine specimen or ACR 2.5 to 25 
mg/mmol in males or 3.5 to 25 mg/mmol in females), 
Table.1.
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• Detection of microalbuminuria 
A lot of dipsticks (such as Clinitek Microalbumin and Chemstrip 
Micral-Test ) are available to detect microalbuminuria  
[49]
 These strips 
are inexpensive and simple to use in clinical setting but may not precise 
and accurate. 
There are Several laboratory techniques available for quantitative 
measurement of microalbuminuria  
[50]
. These techniques have high 
specificity for detection of albumin. The most frequently utilised 
techniques for are immunoassays. Non-immunological techniques for 
quantifying microalbuminuria are also available. These tests are mainly 
based on chromatographic techniques such as size-exclusion high 
performance liquid chromatography (HPLC) 
[50] 
• Confounders of microalbuminuria screening 
There are a lot of confounding factors affect microalbuminuria 
screening and leads to false-positive results . In healthy individuals 
strenuous exercise may increase albumin level in the urine, even above 
the threshold of microalbuminuria 
[51] 
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The mechanism for exercise-induced temporary microalbuminuria 
is not completely established. It may be because strenuous exercise 
causes increase in glomerular filtration pressure which leads to increase 
in glomerular permeability [
51]
 
Another possible confounder is Urinary tract infection (UTI) .So 
the therapeutic guidelines recommend to exclude the samples that show 
positive evidence of UTI and recommend to submit the mid-stream 
specimen of urine (MSSU) forbacteriology [
52]
. Fever, upright position 
for a long time, pregnancy and menstruation are the other confounder of 
microalbuminuria screening [
53].
There is high variability in the excretion 
of albumin in the urine in these conditions. Therefore, re-examination of 
additional samples after a suitable time gap is recommended 
Table.2.
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 Screening methods and number of samples 
There is a general consensus that the gold standard of 
microalbuminuria screening is 24-hour urine collection 
[54]
However, it 
will be difficult for the individual to completely compliant with this 
method so this approach is rarely utilised. One of the simpler and more 
easily accomplished way of timed microalbuminuria measurement is 
Overnight albumin excretion rate  
[55]
 One advantage of overnight urine 
collection is more stable albumin excretion because of minimum 
movement during bedtime  
[56]
 
More commonly used methods are measuring urinary albumin 
concentration (UAC) or ACR on random samples 
[57]
 or first morning 
voids. 
[58]
 The easiest and most convenient method for the patients and 
the practitioners is the random spot urine collection. For collection of 
first morning urine sample, the patient is instructed to empty the bladder 
before going to bed and to collect the first void after awaking up from 
sleep. These methods are minimally affected by biological variations 
and they should ideally reflect the real magnitude of albumin excretion 
in the urine. 
Various studies have recently tried to identify the best method for 
microalbuminuria screening.  In a subset analysis of the PREVEND  
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study, the researchers compared UAC and ACR, both from first morning 
void and random sample; the purpose of the analysis was to identify 
which test better replicated 24-hour urine collection  
[54]
. First morning 
ACR sample was equivalent to 24-hour urine collection with similar 
variability and prevalence. Another subset analysis of the PREVEND 
study revealed that ACR from first morning samples was correlated with 
24-hour urinary albumin excretion (UAE) in predicting cardiovascular 
morbidity and all-cause mortality  after 7.5 years follow-up  
[59]
. 700 
type II diabetics participated in the RENAAL  trial were followed for 3.4 
years  
[59]
According to the  study  ACR was the best predictor for renal 
outcomes. From these studies the reliability of ACR in detecting 
clinically relevant microalbuminuria is clear. 
First morning samples measured by ACR had better reliability in 
microalbuminuria screening because of their exhibition of low 
variability. When there is high urine volume the UAC tends to be 
reduced, as the amount of creatinine filtered over time is relatively 
constant the ACR corrects for variability in urine excretion 
[60]
. Urine 
from first morning void usually reflects the real magnitude of urinary 
albumin excretion without any influence from the confounding factors 
such as exercise. 
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According to Several international guidelines recommendation, 
repeated samples are necessary for diagnosing microalbuminuria (2 out 
of 3 samples should be positive) 
[61]
. The repeated samples are 
recommended in order to overcome the effect of any possible 
confounders of microalbuminuria screening. However, this is difficult to 
achieve in clinical settings, hence the diagnosis of microalbuminuria in 
the majority of studies (especially in hypertension) has been based on 
single samples. 
• Epidemiology of microalbuminuria 
 In different populations with the same clinical condition the 
prevalence of microalbuminuria varies significantly. This variability 
might be due to several factors such as the measurement methods, 
threshold used, instruments or extent of co-morbidities in the study 
population (e.g. in hypertension; mild, moderate or severe) (table  1-2). 
PREVALENCE OF MICROALBUMINURIA IN GENERAL 
POPULATION: 
Indian scenario 
Hitha B,Pappachan J M,Balachandran pillai H,
[62]
: In 150 cases of 
essential hypertension studied, 40 (26.6%) patients had 
microalbuminuria. It was significantly higher in those with longer 
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duration and greater severity (p<0.001 in each) , older age(p<0.001), 
adverse lipid profile (p<0.01) and higher BMI (p<0.04). There was 
increased risk of recent stroke, hypertensive retinopathy and left 
ventricular hypertrophy (29.33%). Gender and history of smoking did 
not pose any risk for microalbuminuria. 
         Sharma V K,Dubey T N,Jain R K 
[63]
: In 50 cases of essential 
hypertension 12 had microalbuminuria. Among 8 newly detected 1 
(12.5%) had microalbuminuria, 25% upto 10 years duration of disease 
and 50% more than 10 years. 12% with stage 1 and 47% with stage 2 
had microalbuminuria. Hence prevalence of microalbuminuria in 
essential hypertension was 24% and found a strong correlation with 
severity and duration of hypertension.
2 
Sabharwal R K,Parduman singh,, 
[64]
: In 174 cases of essential 
hypertension studied , 58(33.3%) had microalbuminuria. The prevalence 
was 34% in males and 30.7% in females. No correlation was found 
between BMI and albumin excretion and also with duration of 
hypertension. Prevalence of microalbuminuria in non-smokers and non-
alcoholics was 20%. The prevalence in smokers,  alcoholics  and both 
alcoholics and smokers was fond to be 35%, 42%, and 41%. The high 
prevalence of microalbuminuria demands the establishment of screening 
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for microalbuminuria and implementation of specific intervention 
methods.  
 The prevalence of microalbuminuria varies according to ethnicity. 
Microalbuminuria is more common in black and Asian populations 
compared with whites. A comparison between South Asian and white 
European populations living in the UK revealed that microalbuminuria is 
significantly more common in Asians (31% versus 20%)  
[65]
. In this 
study, there were no differences between the two populations in terms of 
age, sex or blood pressure levels. Another study compared UAE in 
African Caribbeans, South Asians and white Europeans  
[66]
.  
 The prevalence of increased UAE was higher in African 
Caribbeans than in South Asians and Europeans. In a cohort of 6801 
subjects from different Asian countries (China, Korea, Indonesia, 
Philippines, Singapore, Malaysia) the prevalence of microalbuminuria 
was 39.8%
[67]
.  
 However, in that study, urinary albumin detection was performed 
by semi-quantitative dipsticks and more than 30% of the involved 
subjects had strong family history of cardiovascular or metabolic 
disease. This may partially explain the high prevalence of 
microalbuminuria. In a large epidemiological study based on diabetic 
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subjects attending primary care clinics, hypertensive Hispanic subjects 
and non-hypertensive Asians showed prevalence of microalbuminuria 
higher than that in Whites subjects 
[68]
 
The relation between prevalence of microalbuminuria and gender 
is not clear. According to some studies males have higher 
microalbuminuria prevalence 
[69]
, others reported no gender differences  
[70]
 In the Diabetes Control and Complications Trial/Epidemiology of 
Diabetes Interventions and Complications (DCCT/EDIC) which 
involved type 1 diabetics showed that UAE was associated with male 
gender and this association was because of central obesity (measured as 
waist-hip ratio-  WHR)  
[71]
. When the prevalence was adjusted for 
WHR, no association between gender and UAE was observed. The 
Prevalence of microalbuminuria was significantly higher in females in 
the EPIC-Norfolk study (14.1% versus 8.4%, P<0.001) 
[72] 
Prevalence in subjects with diabetes mellitus
 
In management of diabetes, microalbuminuria screening is 
recommended by the majority of clinical guidelines 
[73]
. Many studies 
addressed the prevalence of microalbuminuria in diabetic individuals. In 
order to examine the development of microalbuminuria, The Oxford 
Regional Prospective Study recruited type I diabetics aged under 16 
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years  
[74]
. According to the study the prevalence of microalbuminuria 
was 25.7% and 50.7% after 10 years and 20 years respectively. Around 
30% of adults with type I diabetes develop microalbuminuria within 18 
years after diagnosis
[75]
 
The United Kingdom Prospective Diabetes Study (UKPDS 64) 
included 5097 type II diabetes patients (67% newly diagnosed) from 
different ethnic origins in their study and followed them for 20 years in 
order to find the progression of diabetic subjects to nephropathy
[76]
. At 
baseline, the prevalence of microalbuminuria of the study population 
was nearly 7% and after the prevalence  5, 10 and 15 years were 17%, 
25% and 28%, respectively.  
Prevalence of microalbuminuria in subjects with hypertension 
Although a number of studies have attempted to define the 
prevalence of microalbuminuria in essential hypertension, the exact 
prevalence is still unclear. The estimated prevalence of 
microalbuminuria in hypertensive subjects from varios studies ranges 
from 4.7% to 58.4% 
[77]
. A longitudinal study involving 1,041 young 
(18-45 years) hypertensives (stage 1) demonstrated that prevalence of 
microalbuminuria was 6% of the study population detected using the 24-
hour method 
[78]
. In this particular study the low prevalence of 
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microalbuminuria mainly because of the young age of the participants ( 
as microalbuminuria tends to be more common among older subjects 
[79]
) and also due to the early stage of hypertension of the subjects. 
  The urine dipstick method seems to overestimate the prevalence 
detection of microalbuminuria. For instance, in Germany in a large 
cohort of non-diabetic hypertensive subjects about  32% had 
microalbuminuria  
[80]
 In this study, the diagnosis of microalbuminuria 
was based on two positive urine dipsticks (Micral-Test) out of three. In 
the i-SEARCH global study the highest prevalence of microalbuminuria 
(58.4%) was observed  from 26 countries Almost 21,000 subjects 
participated in this clinic-based study.The overall prevalence of 
microalbuminuria was high among participating countries, with rates of 
53 to 71% in some developing countries. However, one of the major 
limitation of this study was that the diagnosis was based on a single 
urine specimen measured using urine strips. Also, the majority of the 
study population was diabetic and above 60 years of age and which were 
the causes for the high prevalence of microalbuminuria.  
In summary, the reported prevalence of microalbuminuria has 
been limited by, under-precision caused by single screening, 
measurement method, too many restrictions on population tested or 
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small sample size. The reliable information on microalbuminuria in 
hypertension is limited and thus, the prevalence remains to be 
elucidated. 
Pathogenesis of microalbuminuria  
The pathophysiological mechanisms underlying the proteinuria in 
hypertensive individuals are not completely understood. Various 
mechanisms have been proposed. Most of these mechanisms involve 
alteration in the renal haemodynamics and endothelial changes 
[81] 
The glomerular filtration barrier consists of three layers; the 
endothelium, the glomerular basement membrane and podocyte foot 
processes. Each layer plays important role in preventing some molecules 
from being excreted as an ultrafiltrate. 
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Figure.5 
Glomerular Basement Membrane 
 
 
As mentioned before, the maintainence of the glomerular pressure 
is mainly by afferent arteriole. In hypertension, in order to protect the 
kidney from the high hydrostatic pressure produced by high blood 
pressure the afferent arteriole tends to constrict. Specific cells in the 
distal convoluted tubule also regulates this feedback mechanism 
mediated by constricting the afferent arteriole to maintain GFR  when 
the volume of filtrate is high 
[82]
.Impairment of this autoregulatory 
process which leads to hyperfiltration and passage of albumin into urine 
is induced by prolonged high blood pressure  
[82]
. This hypothesis is 
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supported by an experimental animal model, in which partial 
nephrectomy causes hyperfiltration in the remaining nephrons in order to 
maintain GFR, which in turn led to glomerular hypertension and 
proteinuria 
[83] 
It has been postulated that impairment of glomerular permeability 
is also a major contributor in the pathophysiology of microalbuminuria  
[84]. 
The changes in the structure of the glomerular filtration barrier led to 
alteration of glomerular permeability. Glomerular filtration barrier 
compoed of three layers, they are endothelium covered by anionic 
glycoprotein (glycocalyx), glomerular basement membrane andpodocyte 
foot processes 
[85]
. This barrier prevents some molecules from escaping 
to the lumen of Bowman capsule. As the glycocalyx is negatively 
charged it repells the albumin as it is also negatively charged. Therefore, 
any structural changes could translate into passage of larger amount of 
albumin in the urine. Impairment of the podocytes  
[86,87] 
and glycocalyx  
[88]
  have been shown in diabetic patients with microalbuminuria and 
subjects with hypertensive nephrosclerosis 
[89] 
Impaired function of the renin-angiotensin aldosterone system 
(RAAS)  has also been implicated. Angiotensin II has been found to 
contribute in the sclerosis of the podocytes leading to excretion of large 
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molecules including albumin
[91]
. Activation of angiotensin II type 1 
receptors leads to an increase  in the production of reactive oxygen 
species (ROS) and different inflammatory mediators which mediate 
endothelial injury in the kidney and in the blood vessels
[92,93]
. There is 
significant reduction in microalbuminuria and several biomarkers of 
inflammation and oxidation by inhibition of angiotensin receptors using 
pharmacological approaches and drugs with putative anti-oxidant 
properties, which supports this hypothesis 
[94,95] 
Figure. 6 
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Simple illustration of mechanisms by which malfunction of 
RAAS could mediate albuminuria and atherosclerosis. Adapted with 
permission from 
[90] 
It has been suggested that microalbuminuria is a marker of 
generalised endothelial dysfunction and it also reflects the systemic 
vascular abnormalities which may explain the association of 
microalbuminuria with different cardiovascular diseases 
[96]
. Cottone et 
al.
[97]
 have shown that UAE is correlated well with  levels of various 
adhesion molecules that are involved in atherosclerosis of blood vessels.   
All mechanisms mentioned previously could mediate 
microalbuminuria. As a result of increased blood pressure there is 
alteration in renal hemodynamics which leads to increase in glomerular 
permeability. In addition, defects in renin-angiotensin system leads to 
increased oxidative stress and high levels of inflammatory markers 
which leads to endothelial dysfunction which in turn causes increased 
permeability  
Association of microalbuminuria with diseases and risk factors 
Over the last decade, our understanding of the role of 
microalbuminuria as an important independent risk factor for metabolic 
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and cardiovascular morbidities has expanded exponentially. An 
increasing body of evidence suggests that microalbuminuria is emerging 
as a useful tool for predicting several diseases
[98]
 This is because 
microalbuminuria is reflecting the more complex vascular changes 
which occurs in the body. However, among the clinicians the awareness 
of the association of various diseases with microalbuminuria is still poor. 
A survey among 1700 clinicians (general practitioners, cardiologist and 
diabetologists) in five European countries was conducted  by Haller and 
colleagues
[99]
 to evaluate the awareness of importance of 
microalbuminuria in clinical practice. The vast majority (over 93%) of 
clinicians was aware of the association between microalbuminuria and 
impairment of renal function. There was extremely limited awareness of 
the association of microalbuminuria with abnormalities in other organs. 
For example, among participated clinicians in the UK, only 16%, 
10%, 9%, 8% and 4% were aware of the relation between 
microalbuminuria and eyes, macrovascular,cardiac, microvascular and 
brain complications, respectively. As screening of microalbuminuria is 
easy and relatively inexpensive this finding is disappointing and also of 
the result of the screening may guide the clinician to identify individuals 
who are at high risk for cardiovascular complications. 
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Microalbuminuria and high blood pressure 
There is plausible association between high blood pressure and 
increased UAE. One of the proposed mechanisms and also one of the 
most frequently reported predictors of microalbuminuria is High blood 
pressure 
[100]
. In MAGIC (Microalbuminuria: A Genoa Investigation on 
Complications) study  
[101]
 and Gubbio Population studies 
[102]
 there were 
direct relationships between high blood pressure and microalbuminuria. 
These are the studies that aimed to characterise microalbuminuria in 
non-diabetic subjects with hypertension. This relation was also 
supported by a large cross-sectional study involving 4 subgroups; 1) 
diabetic patients with severe atherosclerosis,2)non diabetic with severe 
atherosclerosis, 3)diabetic with mild atherosclerosis and 4)non-diabetic 
with mild atherosclerosis  
[103]
. In this study, albuminuria was 
significantly associated with high bloodpressure (even below the 
threshold level for the definition of hypertension) in all four groups 
The relationship between increased blood pressure and 
albuminuria has also been reported in studies which using 24-hours 
blood pressure monitoring  There were positive correlations between 
microalbuminuria and 24-hour SBP, DBP and pulse pressure in a small 
group of subjects who are not having any evidence of cardiovascular or 
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metabolic abnormalities 
[104]
 This relationship was also evident in 1) 
diabetic patients  
[105]
, 2) hypertensive subjects with end organ damage  
[106]
, 3)resistant hypertension  
[107]
  and 4) general hypertension 
population  
[108]
. These findings are of particular importance because 
now ambulatory blood pressure is being considered as the gold standard 
for the diagnosis of hypertension and it also helps in the identification of 
subjects with true refractory hypertension
[109]
  and therefore, it will 
represent the most reliable data for the association with 
microalbuminuria. 
People who are lacking the normal blood pressure reduction 
during sleeping ( non-dippers) are associated with increased UAE 
[110]
. 
UAE was related to 1) non-dipping pattern in a cohort of recently 
diagnosed hypertension
[111]
, 2) in subjects with untreated 
hypertension
[112]
  and 3) those with resistant hypertension 
[107] 
Microalbuminuria and renal function 
Microalbuminuria is best recognised for its the association with 
deterioration in kidney fnction. Microalbuminuria may be present at an 
early stage of renal disease, even when eGFR is normal  
[113]
 For the 
prediction of end stage renal disease (ESRD) , recent recommendations 
suggest the use of albuminuria in addition to eGFR 
[114,115]
 In a study 
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which involved almost 66,000 patients and they were followed for ten 
years. The result of the study revealed both eGFR and albuminuria were 
independent predictors for ESRD. This association was also reported 
recently in subjects with high cardiovascular risk and in diabetics who 
are followed for 10 years
[116,117]
 Combining albuminuria and eGFR 
screening identified hypertensives at high risk of cardiovascular 
mortalities and morbidities in a prospective cohort study
[118]
. Increased 
albuminuria was a strong predictor for progression to ESRD in a 
Canadian cohort study with a large number of patients (> 900,000)
[119]
. 
917 non-diabetic hypertensives with normal renal function were 
followed for a median of 11.8 years  in a sub-analysis of the MAGIC 
study, 
[120]
 More than one-third of subjects who developed chronic renal 
insufficiency had increased urine albumin excretion at baseline 
compared with 7% in the control group. The relation of 
microalbuminuria with renal outcome was independent of eGFR or other 
confounders. Likewise in a retrospective study, hypertensive subjects 
were followed for 7 years and decline in creatinine clearance and 
increased cardiovascular events was associated with microalbuminuria  
[121]
in non-diabetic hypertensive subjects Regression. or significant 
reduction of UAE (defined as reduction  exceeds 50%) by drugs were 
associated with better renal outcomes 
[122]
. These findings clearly 
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suggest that microalbuminuria provides more information than that 
provided by eGFR in prediction and identification of impaired kidney 
function. Therefore, routine screening for people at high risk for chronic 
diseases should include albuminuria screening in order to prevent or 
delay the progression to ESRD. 
Microalbuminuria and cntral nervous system 
 Stroke risk 
Results of various cross-sectional and prospective studies suggest 
that microalbuminuria is prevalent in patients with recent acute stroke 
and may predict future stroke events 
[123]
. In a prospective case-control 
study involving patients who are at high risk for developing stroke 
(hypertension, diabetes, transient ischemic attack (TIA) or ischaemic 
heart disease) and patients with recent acute stroke (within a week), the 
prevalence of microalbuminuria in those with stroke was significantly 
higher than that in  the high-risk group (29% versus 10%)  
[124]
. During a 
mean follow-up period of 1.5 years, almost 15% of the high-risk group 
and one-fifth of subjects with recent stroke were developed vascular 
events. In subjects with albuminuria new onset vascular events were 
more frequent even after adjusting other risk factors such as diabetes, 
high blood pressure, and cigarette smoking. 
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The Losartan Intervention For Endpoint reduction (LIFE) 
examined the association of cardiovascular events with 
microalbuminuria in 8206 hypertensives  with LVH 
[125]
., the study 
revealed that for every 10-fold increase in UAE after follow up of the 
subjects  for a median of 4.8 years and the risk for stroke increased by 
50%. However, this result has some limitations. The limitations are 
1)microalbuminuria was detected using only one specimen ,2)did not 
include any measure to exclude those with UTI and 3) the study was 
performed in high-risk population and it is uncertain whether the same 
pattern may be observed in patients without LVH.  
  EPIC-Norfolk study, a general population study in which the 
subjects were followed up for 7.2 years, revealed that there was 50% 
increased risk for stroke in subjects with microalbuminuria 
[126]
. The 
hazard ratio for the association between stroke events and 
microalbuminuria was greater than that for some traditional risk factors 
such as body mass index (BMI), total cholesterol; SBP   was revealed by 
a Cox multiple regression models. In this study the detection of 
microalbuminuria was based on single random sample method which 
may overestimate albuminuria prevalence as discussed previously. 
 
41  
The relation of microalbuminuria with stroke was evaluated by a 
meta-analysis involving twelve studies with more than 48,000 patients. 
The above said studies involved different populations with or without 
different co-morbidities such as, hypertension, cardiovascular disease, 
prior stroke or diabetes mellitus. stroke events was strongly associated 
with microalbuminuria. Comparing the individuals with 
normoalbuminuria, subjects with microalbuminuria had  a 90% greater 
risk for developing future stroke incidents.  
In the survey by Haller et al. 
[100]
, the association of brain 
abnormalities with microalbuminuria was the least recognised 
association. This indicates that clinicians may miss an non-invasive and 
easy technique for identifying individuals at high risk of cerebrovascular 
diseases. 
Cognitive decline and cerebrovascular changes 
The largest body of evidence for the interaction between cognitive 
function and albuminuria (microalbuminuria and proteinuria) comes 
from the the Telmisartan Randomized AssessmeNt Study in ACE 
iNtolerant subjects with cardiovascular Disease (TRANSCEND) and 
Ongoing Telmisartan Alone and in Combination with Ramipril Global 
Endpoint Trial (ONTARGET) 
[127]
. More than 28,000 patients suffering 
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from diabetes mellitus or vascular diseases participated in these trials. 
Cognitive function was assessed by using a 30-point Mini–Mental State 
Examination (MMSE) at baseline and after 5 years to evaluate the 
degree of dementia. Subject people with albuminuria at baseline had 
lower MMSE scores (less than 24) and they also had higher odds for 
reduced cognitive function. Similarly, during  the study those who 
developed albuminuria had increased odds for cognitive impairment. 
One of the major drawbacks of the study is the population studied. The 
conclusions cannot be extended to those without vascular abnormalities 
or diabetes as these disorders may also interact with cognitive decline.  
Ravera and colleagues  
[128]
 investigated the association of 
microalbuminuria with subclinical cerebrovascular changes in a small 
number of untreated hypertensive subjects (11 with microalbuminuria 
and 11 with normoalbuminuria) with no other clinical neurological 
disorders. Using magnetic resonance imaging, the researchers found that 
there was greater prevalence of cerebral lacunar infarcts in subjects with 
microalbuminuria. In a cohort of elderly subjects in Japan, 
microalbuminuria  was correlated  with cerebral small vessels disease 
(SVD) 
[129]
. In addition, in subjects with microalbuminuria  there were 
increased prevalence of ischaemic lacunar lesions and white matter 
hyperintensity. Another cross-sectional study carried out in 2316 elderly 
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subjects showed that dementia and mild cognitive impairment were 
significantly related to microalbuminuria. 
[130]
., revealed 
microalbuminuria was significantly related to deep or infratentorial 
cerebral microbleeds investigated by neuroimaging in 285 hypertensives 
who were not having any evidence of severely reduced renal function 
,stroke, TIA or 
[130]
,.Proteinuria was strongly related to Brain 
microbleeds in patients who had stroke or TIA events  
[131]
.  
These findings are important for various reasons.  
1) Several brain abnormalities such as cognitive decline, age-
associated disorders and stroke has been increasingly linked with 
cerebral SVD  
[132]
.  
2) White matter hyperintensities, which are possibly due to SVD-
induced ischaemia, have been shown to predict cognitive decline, 
stroke, and mortality 
[133] 
3) The association between brain microbleeds and mortality 
[134]
, 
neurological disorders such as Alzheimer’s disease and has been 
suggested. 
The identification of cerebrovascular changes like SVD, cerebral 
microbleeds and white matter lesions are time-consuming, expensive 
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and also they are not routinely requested investigations (ultrasonography 
or special neuroimaging). Microalbuminuria screening possibly serve as 
an appropriate tool for identifying people at high risk for 
cerebrovascular complications.  
Microalbuminuria and cardiovascular abnormalities 
A growing body of evidence links microalbuminuria with 
cardiovascular system abnormalites. As mentioned earlier, 
microalbuminuria is a marker of generalised endothelial dysfunction 
which is a key factor for various cardiovascular diseases such as, 
myocardial infarction, CHD, heart failure, atherosclerosis and 
hyperlipidemia  
Ischaemic heart disease risk 
A number of studies suggest the prognostic value of 
microalbuminuria for ischaemic heart diseases 
[135].
 9 % of the Subjects 
with untreated hypertension and  high-normal blood pressure in the 
Danish MONICA (Multinational Monitoring of Trends and 
Determinants in Cardiovascular Disease) project had future ischemic 
heart disease when  were followed for ten years 
[136]
. The prevalence of 
microalbuminuria in patients developing   ischaemic heart disease was 
higher than that in the control group. After adjusting for known factors 
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such as blood pressure, lipids, gender and BMI the relative risk for 
developing ischaemic attack associated with microalbuminuria was 3.5. 
UK population-based study confirms these findings where future 
episodes of CHD with hazard ratios of 1.36 and 1.59, respectively were 
predicted by microalbuminuria and gross proteinuria following acute 
myocardial infarction the prognostic value of microalbuminuria for short 
and long-term outcomes has also been investigated. Berton et al.  
[137]
 
studied albuminuria in patients admitted for acute myocardial infarction 
and compared findings with a control group (those admitted for 
suspected myocardial infarction but did not meet the diagnostic criteria). 
UAE that was measured by 24-hour urine collection was higher both on 
the day of admission and after 2 days when compared with the control 
group. But, participants in the control group were younger (i.e. not age-
matched) and also had fewer cardiovascular co-morbidities that biased 
the comparison. Another study revealed that increased UAE  was present 
in more than one-third of hospitalised patients with acute myocardial 
infarction 
[138] . 
A strong predictor for myocardial infarction 
complications including mortality was increased UAE 
A study involving 175 non-diabetic patients with acute 
myocardial infarction was followed for 3 years aiming to identify factors 
that were associated with subsequent cardiovascular events or death 
[139]
. 
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Microalbuminuria, that was measured by timed overnight urine 
collection on the third day after the event proved to be an independent 
predictor for both endpoints. Similar findings have also been shown in a 
larger non-diabetic cohort in which cardiovascular complications 
following myocardial infarction episodes were higher than in those 
patients without microalbuminuria  
[140]
 Thus, in patients with 
myocardial infarction, increased UAE might identify those at increased 
risk for complications. future complications may be lowered More 
vigorous treatment. 
Left ventricular hypertrophy and structural changes 
The relation between increased UAE and LVH in a population 
with essential hypertension have been investigated by The LIFE study 
[141]
 nearly 9200 hypertensive subjects with evidence of LVH on 
electrocardiography (ECG) but no evidence of recent stroke, myocardial 
infarction ,low left ventricular  ejection fraction (less than 40%), or 
severe kidney impairment participated. Even possible confounders such 
as high blood pressure, increased age and diabetes were adjusted. Both 
microalbuminuria and proteinuria strongly associated with LVH . 
Data from the Hypertension Genetic Epidemiology Network 
(HyperGEN) revealed that albuminuria has been associated with 
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increased left ventricular size (on echocardiography) in both 
normotensive and hypertensive individuals; reduced ejection  fraction 
has been seen only in microalbuminuric hypertensive subjects  
[142]
 
Various Electrocardiological abnormalities such as intraventricular 
conduction defects, rhythm abnormalities, left axis deviation and 
ventricular repolarisation alterations  were also associated with  
microalbuminuria 
[143]
. 
It has been proven recently that in hypertensive subjects with 
ventricular diastolic impairment, microalbuminuria is related with 
increased ventricular remodelling, stiffness and increased levels of NT-
proBNP which is a marker for heart wall stress  
[144]
 On the other hand, 
reduction in eGFR did not reveal an association with such changes in the 
myocardium. This means that microalbuminuria gave information in 
addition to that offered by the classical marker of kidney disease. The 
significance of such findings is that microalbuminuria could recognize 
those with high risk for progression to heart failure. It could help to 
discover pharmacological agents with properties to prevent such 
progression. 
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Congestive heart failure (CHF) 
An association of microalbminuria with CHF is expected as its 
association with other cardiac outcomes such as CHD and myocardial 
infarction. This association was established in the Candesartan in Heart 
failure: Assessment of Reduction in Mortality and morbidity (CHARM) 
trial
[145]
. Two thousand three hundred and ten patients with heart failure 
took part in the programme. Albuminuria was identified in 41% of the 
patients (30% microalbuminuria and 11% gross proteinuria). Similar 
prevalences were observed after excluding diabetes and hypertension. In 
this patient population, albuminuria was useful functional predictor for 
mortality and further degeneration in the myocardium in the studied 
population.  
The prevalence of  gross proteinuria and microalbuminuria in a 
small group of subjects who participated in the ALiskiren Observation 
of heart Failure Treatment (ALOFT) study was 11% and 33%, 
respectively . Albuminuria was detected by dipstick in an Asian 
population and it was associated with CHF with preserved left 
ventricular ejection fraction and predicted future death  
[146]
. In 
hypertensive subjects with LVH in the LIFE study, albuminuria was 
correlated with twofold increase in risk of incident heart failure
 [147]
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In the general population, data from the Multi-Ethnic Study of 
Atherosclerosis (MESA) which involved 6,800 individuals with 
different ethnic background determined that albuminuria was the 
strongest predictor of new-onset CHF 
[148]
 .Though the follow-up period 
(4 years) was too short for estimation of such an outcome, this study is 
particularly interesting for several reasons. Firstly, it explained the 
incidence of severe cardiac outcome in apparently healthy subject 
without clinically detectable cardiovascular disease. Secondly, the study 
included subjects from four different ethnicities; Caucasians, 
black,Asian and Hispanics. At the end, the researchers demonstrated the 
association between   heart failure and microalbuminuria even after 
adjusting for traditional risk factors. This observation recommends that 
albuminuria is important in risk stratification for severe cardiac 
outcomes. 
Vascular diseases 
Arterial stiffness that was measured by pulse wave velocity 
(PWV) has been reported in subjects with microalbuminuria
[149]
. This 
condition is a risk factor for future cardiovascular events
 [150]
 . Loss of 
arterial elasticity leads to increase in the force of contractions of the 
heart which in turn might lead to LVH and severe complications 
[150,151]
. 
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In subjects without hypertension or diabetes, arterial stiffness was 
associated with microalbuminuria after adjusting for possible 
confounders  
[152]
 In small groups of untreated hypertensive subjects, the 
prevalence of microalbuminuria in those with arterial stiffness that was 
measured by carotid / femoral arteries PWV or ambulatory arterial 
stiffness index was notably higher  
[153]
. The association remained vital 
in adjusted regression models. 
 
Microalbuminuria has been also related with coagulation 
abnormalities. A sub-analysis from the PREVEND study described an 
increased incidence of venous thromboembolism in subjects with  
microalbuminuria 
[154]
. The incidence rate was 0.40% per year for those 
with UAE ≥ 30 -300 mg per day compared with only 0.12% per year for 
those with UAE <15 mg per day (P<0.001). A recent post-hoc analysis 
of the PREVEND study indicated that microalbuminuria was also 
related to increased risk for recurrent venous thromboembolism 
[155]
 
A direct relationship between albuminuria and atherosclerosis has 
been noted in many studies. Both these conditions share a common 
pathological mechanism, endothelial damage. In a Norwegian study, a 
direct relation between ACR and de novo formation and progression of 
atherosclerotic plaque in the carotid artery has been reported in subjects 
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without diabetes.Moreover, microalbuminuria revised the formation and 
the progression of early marker of atherosclerotic lesion in the carotid 
artery (calcification) in clinically health individuals who participated in 
the MESA study  
[156]
Increased carotid intima-media thickness, a risk 
factor for atherosclerosis, was also reported in hypertensive subjects 
with microalbuminuria 
[157]
 
RISK FACTORS FOR STROKE 
1. Age: 
        Increasing age results in increased incidence of stroke. Stroke is 
found to be 25 times more common in people aged 75-84 years than in 
people aged 45-54 years. 
2.  Sex:  
 There is slight male preponderance in middle and old age. 
 TIA and thrombotic are more common in male 
 Embolic stroke more common in female. 
 Stroke morbidity is high in males 
 In various studies male to female ratio is high(5.5;1 according 
toaganial et al. and 3.2;1) 
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3. Blood Pressure: 
 Hypertension is strongly associated with stroke risk, the risk 
being present for both systolic and diastolic BP.
13,14 
The age adjusted 
relative risk for cerebrovascular disease in hypertension was 3.1 for 
men and 2.9 for women.
15
 
4. Smoking: 
 It is established that there is dose-response relationship, 
affecting both sexes in all age groups. Even passive smoking increases 
the stroke risk.  
 The number cigarettes smokes per day is directly proportional to 
CVA risk. 
 As per Framingham study, 16 year followup shows CVA is three 
times more common in smoker than nonsmoker. 
5. Blood lipids:  
              The relationship between blood lipids and stroke is much 
weaker than that for coronary artery disease, but serum lipoprotein 
(a) is found to be predictive.
17
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6. Diabetes Mellitus:  
          Patients with diabetes have double the risk of stroke compared to 
non-diabetics.
18 Stroke in diabetics is more likely to be fatal.
19
 
7. Haemostatic variables:  
        Increased fibrinogen, raised plasma coagulant activity, reduced 
blood fibrinolytic activity, raised von Willebrand factor and raised 
haematocrit are all risk factors for stroke.
21, 22
 
8. Atrial Fibrillation:  
       AF, acts as the most frequent cardiac source of embolism to the 
brain. 
9. Alcohol:  
       Alcohol also raises the BP, 
25 alters blood lipids, causes AF and 
cardiomyopathy and  this may  increase stroke risk. 
10. Obesity: 
       Stroke risk increases particularly if the weight has been gained in 
middle age or has fluctuated substantially or compounded by 
hypertension and diabetes.
25
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11. Diet:  
       Omega-3 polyunsaturated fatty acids and less saturated fatty acid 
consumption may reduce stroke risk.
27 Excessive salt intake may 
increase blood pressure and increases stroke risk.
28 High intake of 
potassium reduces the stroke risk by lowering blood pressure.
29
 
12. Exercise:  
       Reduces the risk of NIDDM, thus reducing stroke risk. 
13. Non-stroke Vascular Disease:  
          Coronary artery disease, asymptomatic peripheral vascular   
disease    and    TIA    are    all    associated    with    increased stroke 
risk.
31, 32 
14. Genetic Factors:  
          Various vascular anomalies; connective tissue disorders like 
Ehler-Darlos Syndrome, Pseudoxanthoma elasticum, Marfan's 
syndrome,  
 Fibromuscular hypoplasia, MVP; hematological diseases like 
sickle cell disease, anti-thrombin III deficiency, protein deficiency, 
dysfibrinogenemia; familial hypercholesterolaemia; cerebral amyloid 
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angiopathy; homocysteinemia; Fabry's disease; cardiac myxoma; 
mitochondrial cytopathy etc are associated with increased risk of 
stroke.
33 
CAUSES OF ISCHEMIC STROKE
34 
Causes of ischemic stroke 
Common causes 
Thrombosis 
• Lacunar stroke 
• Large vessel Thrombosis 
• Dehydration 
Embolic occlusion 
• Artery-to-artery 
▪ Carotid bifurcation 
▪ Aortic arch 
▪ Arterial dissection 
• Cardioembolic 
▪ Atrial Fibrillation 
▪ Mural thrombosis 
▪ Myocardial infarction 
▪ Dilated cardiomyopathy 
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Valvular lesions 
▪ Mitral Stenosis 
▪ Mechanical valve 
▪ Bacterial Endocarditis 
▪ Paradoxical embolus 
▪ Atrial Septal defect 
▪ Patent Foramen ovale 
▪ ASD 
▪ ECHO contrast 
Hypercoagulable disorders 
• Protein C deficiency 
• Protein S deficiency 
• Anti-thrombin III deficiency 
• Anti-phospholipid syndrome 
• Factor V Leiden Mutation 
• Prothrombin G 20210 Mutation 
• Systemic malignancy 
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• Sickle cell anemia 
• Thalassemia 
• Polycythaemia vera 
• Systemic lupus erythematosus 
• Homocysteinemia 
• Thrombotic thrombocytopenic purpura 
DIAGNOSTIC APPROACH IN STROKE PATIENTS 
• The rapid evaluation of patient is essential for use of time-
sensitive treatments such as thrombolysis. 
• An adequate history from an observer is essential. 
• Once the stroke is diagnosed, a brain imaging study is 
necessary to determine if the cause of CVA is ischaemic or 
hemorrhagic. 
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BASIC INVESTIGATION 
Hematological investigation ; 
 Complete hemogram 
 Hematocrit 
 Prothrombin time 
 Activated partial thromboplastin time  
 Peripheral smear 
Biochemical investigation; 
 Fasting blood glucose 
 Lipid profile 
 Blood urea  
 Sr. creatinine 
 Sr. electrolytes 
 Liver function tests 
 Urine routine 
59  
Other  investigations; 
 X-ray chest 
 ECG 
 Echocardiography  
Special investigations 
 Computerized tomography 
 MRI 
 USG 
 Doppler  
 Digital subtraction angiography 
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TREATMENT34 
Management includes; 
• Supportive care 
• Intravenous thrombolysis 
• Endovascular methods 
• Antithrombotic treatment 
• Neuroprotection and stroke 
Supportive care 
To maintain perfusion to the area surrounding the infarction 
Prevention of complication- 
 Infection 
 Deep vein thrombosis 
Blood pressure maintenance 
Good glyceamic control 
Anti edema measures 
Special care in cerebellar infarction 
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Medical support 
• Protection of airway to avoid obstruction, hypoventilation and 
aspiration. 
• Maintenance of body temperature to prevent hyperthermia. 
• Maintenance of blood glucose less than 200 mg/dl and BP 
around 150 mmHg. 
• Maintenance of nutritional status and fluid requirement. 
• Watch for brain edema and treat it with mannitol. 
• Bowel and bladder care, prevention of pressure sores and 
infections. 
Thrombolysis 
IV rtPA at a does of 0.9 mg/kg within 3 hours of stroke onset 
seems to have a role in the treatment of acute ischaemic stroke. 
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Table 3 
Administration of intravenous Recombinant Tissue Plasminogen 
Activator (rtPA) for acute ischemic stroke 
Indication 
Clinical diagnosis of stroke. 
Onset of symptoms to time of drug administration < 3 hrs. 
CT scan showing no hemorrhage or significant edema. 
Age > 18 years. 
Consent by patient or surrogate. 
 
Anti-platelet drugs:  
 Ingestion of aspirin within 48 hrs of stroke onset reduces both 
stroke recurrence and mortality. Agents that act at glycoprotein II b/III 
receptors are under trial. 
Anti-coagulation: 
 Trials not support the use of heparin or other anticoagulants for 
patients with atherothrombotic stroke.. 
Neuroprotection:, 
     Excitatory amino acid pathway blockers etc., are under trial. 
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Rehabilitation: 
             It includes early physical, occupational and speech therapy. 
PRIMARY AND SECONDARY PREVENTION 
1. General principles 
• Life style modification. 
• Evaluation of patients clinical risk profile and control of risk 
factors like hypertension, hyperlipidemia, diabetes etc. 
• Use of alternate day aspirin in high risk patients. 
2. Atherosclerotic Risk factors 
• Use of Angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers. 
• Use of statins. 
3. Anti-platelet drugs 
 Aspirin, Clopidogrel and combination of Aspirin and dypridamole 
are used. 
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4. Anti-coagulation therapy:  
 Used in embolic stroke to maintain INR 2-3. 
PROGNOSTIFICATION  IN ACUTE STROKE 36 
The stroke outcome  may be influenced by many variables: 
Demographic variables 
Includes age, gender and race.  
Young better than in old,  
married than in the unmarried,  
rural areas than urban areas and  in those discharged home than 
in those transferred to long term care hospitals. 
General Medical Characteristics 
HT,DM,CAD,AF,OBESITY,DYSLIPIDEMIA,SEDENTARY 
LIFE STYLE are associated with increased risk of recurrent stroke and 
thereby would influence long term survival.  
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Comorbidities like heart disease, COPD, peripheral vascular 
disease, Parkinson's disease, polyneuropathy, osteoarthritis etc have a 
direct effect on functional recovery and compound the patient’s 
disabilities. 
Lesion related variables 
Survival is better in infarction than in hemorrhage.  
Anterior circulation infarcts have higher risk of death and so 
also intracerebral or subarachnoid hemorrhage.  
Occurrence of coma at stroke onset reflects severity and is an 
important predictor of 30-day survival. 
    Severity of paralysis, urinary and bowel incontinence also adversely 
influence the outcome. 
Specific therapy intervention 
Better management of respiratory and cardiac problems in acute 
phase may result in decreased mortality. 
Biochemical variables 
 Protein C and S have been found to be decreased in some patients 
with ischemic stroke and predict adverse outcome.  
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      Lipoprotein (a) is found to be an independent risk factor for 
arteriovascular disease.  
      Recent studies have suggested that presence of microalbuminuria 
is associated with poor stroke outcome. 
OUTCOME PREDICTION IN INDIVIDUAL PATIENTS 
The scoring system used in this are; 
1. National Institute of Health Stroke Scale. 
2. Canadian Stroke Scale. 
3. Scandinavian Stroke Scale. 
4. Orpington Prognostic Scale. 
5. Fugl-Meyer Assessment. 
6. Barthel Index. 
7. Communication Index. 
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Of these, the features of the scoring systems used in this study are: 
Table-4 
Scandinavian Stroke Scale 
Function Score 
Prognostic 
score 
Long term 
score 
Consciousness:    
Fully conscious. 6   
Somnolent can be awaked to 
full consciousness. 
4   
Reacts to verbal command, 
but not fully conscious. 
2   
Eye movement    
No gaze palsy. 4   
Gaze palsy present. 2   
Conjugate eye deviation. 0   
Arm, motor power    
Raises arm with normal 
strength. 
6   
Raises arm with reduced 
strength. 
5   
Raises arm with flexion in 4   
68 
  
elbow. 
Can move, but not against 
gravity. 
2   
Paralysis. 0   
Leg, Motor power    
Normal strength. 6   
Raises straight leg with 
reduced strength. 
5   
Raises leg with flexion of 
knee. 
4   
Can move, but not against 
gravity. 
2   
Paralysis. 0   
Orientation    
Correct for time, place and 
person. 
6   
Two of these. 4   
One of these. 2   
Completely disorientated. 0   
Speech    
No aphasia. 10   
Limited vocabulary or 6   
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incoherent speech. 
More than yes / no, but not 
longer sentences. 
3   
Only yes/no or less. 0   
Facial palsy    
None/dubious. 2   
Present. 0   
Gait    
Walks 5 M without aids. 12   
Walks with aids. 9   
Walks with help of another 
person. 
6   
Sits without support. 3   
Bedridden / wheel chair. 0   
Maximal Score 0-52   
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Table 5 Barthel Index
38 
Activity Score
 
Feeding 
O = unable. 
5 = needs help cutting, spreading butter etc. or 
requires modified diet. 10- independent. 
 
 
0 
 
 
5 
 
 
10 
 
Bathing 
O = dependent. 
5 = independent (or in shower). 
 
0 
 
5 
  
Grooming 
O = needs to help with personal care. 
5 = independent face / hair / teeth/ shaving 
(Implements provided). 
 
0 
 
5 
  
Dressing 
O = dependent. 
5 = needs help but can do about half unaided. 
10 = independent (including button, zips, laces 
etc). 
 
 
0 
 
 
5 
 
 
10 
 
Bowels 
O = incontinent (or needs to be given enemas). 
5 = occasional accident.  
10 = continent 
 
 
0 
 
 
5 
 
 
10 
 
Bladder 
O = incontinent or catheterized and unable to 
manage alone  
5= occasional accident 
10 = continent. 
 
 
0 
 
 
5 
 
 
10 
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Toilet use 
O = dependent. 
5 = needs some help but can do something 
alone.  
10 = independent (on and off, dressing, wiping). 
 
 
0 
 
 
5 
 
 
10 
 
Transfers (bed to chair back) 
O = unable, no sitting balance. 
5 = major help (one or two people, physical) 
can sit.  
10 = minor help (verbal or physical). 
15 = independent. 
 
 
0 
 
 
5 
 
 
10 
 
 
15 
Mobility (on level surfaces) 
O = immobile or < 50 yards. 
5 = wheel chair independent, including corners 
> 50 yards. 
10 = walks with help of one person (verbal or 
physical) > 50 yards  
15 = Independent 
 
 
0 
 
 
5 
 
 
10 
 
 
15 
Stairs 
O = unable. 
5 = needs help (verbal, physical, carrying aids).  
10 = independent. 
 
 
0 
 
 
5 
 
 
10 
 
Total [0 - 100] 
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STUDIES RELATING MICROALBUMINURIA and ISCHAEMIC 
STROKE 
Although microalbuminuria is associated with clinical risk factors 
for stroke including diabetes, hypertension, aging, history of 
myocardial infarction and left ventricular hypertrophy there was little 
information regarding microalbuminuria being independent risk factor 
for stroke or as predictor of stroke outcome. But, in recent times, 
several studies have been conducted to ascertain any relationship 
between microalbuminuria and ischaemic stroke. 
Damsgaard EM et al followed 216 people who had been 
selected as control subjects for diabetics during a systematic screening 
for diabetes mellitus among all  people  aged  between  60-74  years,  
living  in  municipality  of  Fredericia, Denmark, between Feb 1981 
and Dec 1987. Extensive clinical and biochemical examination found 
median urinary albumin excretion rate of 7.52 mcg/ min. 8 of those 
with a rate below the median died compared to 23 with a rate equal to 
or greater than the median.  The median albumin excretion rate in the 
31 who died was 15 mcg/min and cardiovascular disease was the main 
cause of death in both groups.67 
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1. Yudkin et al used Islington Diabetes Survey in 1988 to study 
urinary albumin excretion and found that urinary albumin 
excretion had skewed distribution with maximum rate of 191.9 
mcg/min. There was significant correlation between albumin 
excretion rate and systolic BP, diastolic BP and 2 hour blood 
glucose, but not with age, sex or body mass index.
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2. Heikke Miettinen et al followed up cohorts of non-diabetics 
[n=1375] and NIDDM [n=1056] subjects in Finland between 
1982 and 1990 and found elevated urinary albumin excretion in 
25% non-diabetics and 58% of NIDDM patients. All case 
mortality was higher both in non-diabetic and NIDDM subjects 
with borderline or clinical proteinuria, than  in those without 
proteinuria.
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3. Mlacak B et al studied the frequency of albuminuria in patients 
with and without diabetes (138/160) randomly selected from a 
stratified sample comparable with known diabetes by age, sex 
and profession in Metlika country, Slovenia between 1994 to 
1998. The groups were examined in the same way and 
mortality was followed over 5 years. Albuminuria was 
significantly high in diabetics, peripheral arterial disease, 
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hypertension, coronary heart disease and hyperlipidemia. The 
albuminuria was frequent in those who died in the observed 5 year 
period.
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4. Nancy B. Beamer et al conducted a study in Portland Veterans 
Administration and Oregon Health Sciences University Hospital 
in Portland around 1999 and found that microalbuminuria was 
3 times more prevalent in patients with recent stroke (29%) 
than in those with clinical risk factors for stroke (10%) and 
was undetectable in healthy  elderly  controls.  During  follow  
up  period  of 1.5+0.9 years, 20% of patients with recent stroke, 
14% with risk factors for stroke and 0% of healthy elderly 
volunteers had vascular end points with events being as frequent   
in   patients   with   microalbuminuria   (32%)   as   in   patients   
with macroalbuminuria (33%).
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5. Yuyun MF et al conducted a population based prospective cohort 
study in British population consisting of 23,630 individuals 
between 40-79 years, and followed them up for 7 years (1993 - 
1997), with baseline albuminuria tested. A total of 246 stroke 
events occurred. Age adjusted incidence of stroke increased 
significantly across categories of baseline albuminuria. They 
concluded that microalbuminuria is independently associated 
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with approximately 50% increased risk of stroke in the general 
population.
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6. Hans. L. Hillege et al conducted PREVEND (Prevention of 
Renal and Vascular End Stage Disease) study in Groningen, 
Netherlands around 2001 and found that increased level of 
albuminuria was more frequent with advanced age, male sex,  
diabetes, hypertension, hyperlipidemia, smoking etc. Although 
micro and macroalbuminuria was found more frequently in 
diabetic and hypertensive sub group, microalbuminuria was still 
prevalent in 6.6% of the non diabetic, non-hypertensive subjects 
and independently associated with cardiovascular risk factors and 
morbidity.
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7. Turaj W et al conducted a study on 52 patients in stroke unit 
of Neurological Department in Jagiellonian University, 
Caracow, Poland within 24 hours after stroke onset (2001). 
Microalbuminuria was found in 24 of 52 stroke patients 
(46.1%) and in 5 of 37 controls (13.5%) (p<0.05). Patients 
with microalbuminuria scored lower on the Scandinavian stroke 
scale than patients without microalbuminuria, both on admission 
and later.
74
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TESTS FOR MICROALBUMINURIA 
Several methods have been described for measurement of urinary 
albumin excretion with emphasis on unexpensive, easy to apply, rapid 
tests which can be used on a large scale population. The various 
methods used are: 
 Dipstick method. 
 Semi quantitative method. 
1. 1.Chemical precipitation (Sulphosalicyclic acid 
trichloroacetic acid) 
2. Immuno precipitation (Micral Test). 
 Photometric method. 
 Nephelometric method. 
 Sensitive Quantitative methods 
1. Radio immuno assay. 
2. Cellulose acetate, agarose gel electrophoresis. 
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The procedures of various important methods include the following: 
Dipstick method:  
 Chemically impregnated dipstick contains methyl red and 
bromophenol blue with buffering salts. The later dissolve on contact 
with urine and protein in the urine lowers the pH turning it green. It was 
traditionally known to detect albuminuria >300 mg/L and hence not 
advocated for screening for microalbuminuria. But, in a study by 
Alfredo Pegoraro et al, they found that the combination of 
sulfosalicylic acid testing and chemstrips was as good as and less 
expensive than Micral-Test in ruling out microalbuminuria.
76 
Chemical precipitation (Sulphosalicylic acid test):  
 5 drops of 20% Sulphosalicylic acid is added to 3 ml of urine 
in one test tube. This test tube is compared with test tube of untreated 
urine held against a dark background, immediately and turbidity is taken 
to indicate proteinuria.
77 
Immunoprecipitation (Micral test):  
 It is based on color shift of monoclonal antibody to human 
albumin labelled with gold. Here Gold Labelled Optically Read 
Immuno Assay detects microalbuminuria. A specimen of the urine 
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sample passes via the wick fleece into the conjugate fleece. Any 
albumin present in the urine binds itself specifically to the gold labelled 
antibodies. Excess antibodies are bound by immobilized albumin in the 
capture matrix. Only antibodies bound to albumin from the urine 
sample can pass through the capture matrix.
 
These gold-labelled antibodies flow to the detection pad and 
turn it red. Test is performed on early morning random urine sample 
by immersing the strip for 5 sec and reading the result at 2 min, 
visually comparing with color blocks on vial (0 mg/l, 20mg/l, 50 mg/l 
and 100 mg/l albumin).
77 
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Fig. 7: Principle of Micral Test 
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Fig. 8: Method of using Micral Test 
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Radioimmuno assay:  
 It is the "gold standard" for estimation of albuminuria.  It is a 
double antibody technique where albumin in the sample has to compete 
with the fixed amount of  125I.  Labelled  albumin  for  the  binding 
sites of the specific antibodies. Bound and free albumin is separated 
by addition of a second antibody immuno absorbent followed by 
centrifugation and decanting. The radio activity in the pellet is 
measured with a C-counter, Albumin concentration in the sample is 
inversely proportional  to the radioactivity. The sensitivity for RIA 
method was  0.3 mg/l. 
TREATMENT OF MICROALBUMINURIA 
Control of Blood pressure:  
 Systolic BP is one of the most relevant determinants of 
microalbuminuria. Studies of secondary prevention have shown that 
blood pressure reduction effectively reduces the albumin excretion 
rate. Among anti- hypertensives, ACE inhibitors and Angiotensin 
receptor blockers seem to be particularly effective.78 The target BP 
should be < 140/90 mmHg in non-diabetics and  < 130/80 mmHg in 
diabetic patients. 
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Glycemic control:  
 adequate glycemic control can significantly reduce the risk of 
development of microalbuminuria and overt nephropathy in people with 
diabetes. 
Treatment of Dyslipidaemia:  
 Statins modify endothelial dysfunction, inflammatory response, 
plaque vulnerability and thrombus formation.  Their usage is known to 
slow progression of microalbuminuria and is associated with 
stabilization of UAE.
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Smoking cessation:  
 Smoking should be strongly discouraged in patients with 
microalbuminuria not only to retard the progression of 
microalbuminuria but also to guard against cardiovascular disease. 
Protein restriction:  
 Animal studies have shown that restriction of dietary proteins 
intake reduces hyper filtration and intraglomerular pressure hence 
retarding the progression of microalbuminuria. The general consensus 
is to prescribe a protein intake of 0.8 g/mg/day in patients with overt 
nephropathy. 
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MATERIALS AND METHODS 
Study Centre : 
 Coimbatore Medical College and Hospital  
Study Period  
 From September 2013 to August 2014 
Sample Size :  
 60 non diabetic patients with Recent ischemic stroke.  
Method of Study 
 Prospective observational study. 
Inclusion criteria 
 Patients of any age and both sexes with first time ischemic stroke 
within 24 hours of onset of symptoms, the diagnosis of stroke being 
established by WHO definition of stroke. 
 Ischemic lesion confirmed by CT Scan brain. 
 Informed consent obtained from all patients. 
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Exclusion criteria 
Patients with hemorrhagic stroke. 
 Patients with diabetes, defined as fasting plasma glucose > 126 
mg/dl or 2-hour plasma glucose > 200 mg/dl during an oral glucose 
tolerance test or use of antidiabetic drugs. 
 Patients with hypertension, defined as systolic blood pressure > 
140 mmHg or diastolic blood pressure > 90 mmHg or the use of anti-
hypertensive medication. 
 Systemic infection including bacterial meningitis. 
a) Nephropathy and abnormal urinalysis. 
b) Major trauma and surgery. 
c) Previous history fo stroke 
• Detailed history, clinical examination and relevant 
laboratory investigation were done as per the proforma. 
• The severity of stroke was assessed using Scandinavian 
Stroke Scale. 
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Stroke can be classified into three categories: 
MILD 4 
MODERATE 3-2 
SEVERE 1-0 
 
MEDICAL RESEARCH COUNCIL SCALE: 
Grade 0 :  No Contraction 
Grade 1 :  Flicker of contraction 
Grade 2 : After elimination of  gravity,there may be active 
movements 
Grade 3 : Active movements against gravity  
Grade 4 : Active movements against gravity and against some 
amount of resistance 
Grade 5 : Normal power 
In the selected patients, the following investigations were done. 
1. CT scan brain (plain) to establish the ischemic lesion. 
2. Urinalysis, to exclude hematuria, leucocyturia, glucosuria and 
proteinuria. 
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3. Serum glucose levels, blood urea, serum creatinine and fasting 
lipid profile,LFT were estimated. 
4. ECG, chest x-ray  were done to assess the cardiac status. 
5. The albumin excretion rate was assessed using Micral test on 
early morning urine sample and expressed as --------- mg/L. 
Microalbuminuria was defined as urinary albumin excretion rate 
between 30-300 mg/L. 
 After discharge from the hospital, patients were re-examined 6 
weeks later to measure the stroke outcome including mortality from 
any cause and the capacity to perform the activities of daily living 
(ADL) using Barthel Index. 
 The patients with microalbuminuria were screened for stroke risk 
factors and assessed for, fasting serum glucose, WBC count, total 
cholesterol, LDL, HDL and triglycerides. 
Method of statistical analysis 
The data was collected and entered in Microsoft excel. The 
graphs and tables were generated using Microsoft Word and Excel. 
The analysis of the data was done using the statistical Software 
namely SPSS 11.0 and Systat 8.0. Chi-square and Fisher Exact Test 
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were used to test the significance of proportions of predisposing 
Factors and presence of microalbuminuria between cases and controls. 
Similar tests were used to find the significance of proportion of 
presenting factors and age between the microalbuminuria positive and 
negative patients. Student t test (Two tailed) was used to test the 
significance of mean pattern of parameters between cases and controls 
and microalbuminuria positivity and negativity. 
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RESULTS AND ANALYSIS 
Study Design 
This prospective study consisting of 60 recently developed  stroke 
patients as divided in to two groups as patients with 
microalbuminuria(31) and patients without microalbuminuria(29)  had 
the following findings 
Table - 6   
Age distribution 
Age in years 
With MA Without MA 
Number % Number % 
<20 1 3.2 0 0 
21-30 4 12.9 5 17.3 
31-40 5 16.1 4 13.8 
41-50 6 19.3 5 17.3 
51-60 10 32.2 8 27.6 
61-70 4 12.9 6 20.7 
61-70 4 12.9 6 20.7 
>70 1 3.2 1 3.4 
Total 31 100.00 29 100.00 
Mean +SD 47.19+14.03 48.69+15.23 
Inference Two groups are age matched with p=0.693 
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Figure -9 Age distribution 
 
 
 
Among the patients with microalbuminuria, the youngest patient 
was 19 years old and the oldest patient 77 years. The mean age was 
49.94 +15.01 years. 
Among the patients without microalbuminuria, the youngest 
patient was 21 years and oldest patient was 74 years. The mean age 
was 49.00+14.77 years. 
 Hence the two groups were age matched with p=0.693. 
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Table 7 
Sex distribution 
Age in years 
With MA (n=31) Without MA (n=29) 
Number % Number % 
Male 20 64.5 21 72.4 
Female 11 35.5 8 27.6 
Total 31 100 29 100 
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Figure 10 
Sex distribution 
 
 
 
 Among the patients with MA, 20 (64.5%) were male patients 
while 11 (35.5%) were female patients. Among the patients without 
MA, 21 (72.4%) were male patients and 8 (27.6%) were female 
patients.  Hence the cases and controls were sex matched. 
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Table 8 
Side of paucity of movements patients with microalbuminuria 
 
Paucity of 
movements 
With MA (n=31) 
Number % 
Left 16 51.38 
Right 15 48.62 
Total 31 100 
 
Figure 11 
Paucity of Movements 
 
 
Among  the patients with MA,  15  (48.62%)  had  right-sided  
hemiparesis,  16  (51.38%)  had left-sided hemiparesis .  
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Table 9  
Predisposing factors 
Predisposing factors With MA(n=31) 
Without 
MA(n=29) 
p value 
Smoking 19 (61.29) 5 (17.27) 0.038 
Alcohol 12 (41.4) 10 (32.3) >.05 
History of previous 
vascular events 
12 (38.70) 2 (6.89) 0.043 
Inference The predisposing factors are statistically not similar 
between two groups (p<0.05) 
 
Figure 12 
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 In the study population, the  predisposing  factors  included  
smoking  being 19 (61.29%) in patients with MA and 5 (17.27%) in 
patients without MA and alcoholism being 12 (41.4%) in patients with 
MA and 10 (32.3%) in patients without MA. 
 
The history of previous vascular events including ischemic 
heart disease and peripheral vascular disease was found in 12(38.70%) 
of patients with MA and 2(6.89%) of patients without MA. 
j
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Table 10 
Association of presenting factors with Microalbuminuria 
S.No 
Presenting 
factors 
Microalbuminuria  
Total 
(n=60) 
 
p value 
Absent 
(n = 29) 
Present 
(n=31) 
1. Loss of 
consciousness 
2 12 14 0.043* 
2. Aphasia 8 7 15 p>0.05 
3. Seizures 1 1 2 0.534 
4. ECG/IHD 1 2 3 0.036* 
5. Headache 2 - 2  p>0.05 
6. Vomiting - - - - 
7. Giddiness 2 - 2  p>0.05 
8. Smoking 5 19 24 0.038* 
9. Alcohol 10 12 22 p>0.05 
10. H/o PVE 2 12 14 0.043* 
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Figure – 13 
Association of presenting factors with Microalbuminuria 
 
 
Patients had presented with paucity of movements on one side 
with loss of consciousness   (23.33%), aphasia  (20.00%),  seizures  
(3.33%)  headache  (3.33%)  and  giddiness (3.33%). 
The loss of   consciousness was more common in patients with 
microalbuminuria (30.70%Vs.6.89%) and reached statistically 
significant levels. 
The history of smoking was n o t  similar among patients with 
and without microalbuminuria. 
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History of peripheral vascular event was higher in patients with 
microalbuminuria (41.37% Vs 6.89%), which was statistically 
significant. 
ECG / IHD changes of ischemic heart disease was found in 8 
(25.80%) patients with microalbuminuria while 1 (3.44%) of patients 
without microalbuminuria and reach statistically significant level. 
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Table 11 
Association of age / sex with the presence of microalbuminuria 
S.No 
Presenting 
factors 
Microalbuminuria 
 
Total (n=60) 
Absent 
(n = 29) 
Present 
(n=31) 
1. Age in years  
(Mean + SD) 
48.89.+15.23 47.19+14.03 0.128 
2. Sex Male=21 
Female=8 
Male=20 
Female=11 
0.235 
  
Inference 
Age and sex are not statistically associated 
with the presence of microalbuminuria 
(p>0.05). 
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Figure 14 
Association of age / sex with the presence of microalbuminuria 
COMPARISON OF MEAN AGE
47.19
48.69
46
46.5
47
47.5
48
48.5
49
With  microAlbuminuria Without microalbuminuria
With  microAlbuminuria Without microalbuminuria
 
Of the 31 patients  with  microalbuminuria,  16 patients  were  
above the  age  of 50 years but age was not statistically associated 
with presence of microalbuminuria (47.19+14.03Vs. 48.69+15.23). 
Among the patients with microalbuminuria 20 were male and 
11 female. Hence, gender was not statistically associated with presence 
of microalbuminuria. 
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Table 12 
Mean pattern of parameters 
 
Parameters 
(Mean + SD) 
Pt with MA 
(n=31) 
Pt without MA 
(n=29) 
p value 
SBP mm Hg 117.36+9.83 117.48+10.32 0.961 
DBP mm Hg 75.36+5.30 74.76+4.91 0.654 
RBS 108.13+13.65 107.66+11.47 0.885 
Blood Urea 27.16+5.23 24.40+4.19 0.021 
Serum 
Creatinine 
0.94+0.17 0.83+0.14 0.042 
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Figure-15 
Systolic BP 
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Figure-16 
Diastolic BP 
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Figure-17 
RBS 
RBS
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 Blood pressure was found to be similar between patients  with 
microalbuminuria and without microalbuminuria. 
Blood Sugar was 108.13+13.65 among patients with 
microaluminuria while 107.66+11.47among patients without 
microalbuminuria  and was statistically insignificant. 
Among patients with microalbuminuria, blood urea was 
26.56+5.01, serum creatinine was 0.92+0.15 while in patients without 
microalbuminuria,  it was 24.10+2.99 and 0.85+0.12 respectively. 
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Table 13 
Mean Pattern of Lipid Parameters 
Parameters 
(Mean +SD) 
With MA 
(n=31) 
Without MA 
(n=29) 
p value 
Triglycerides 192.45+35.59 157.93+33.49 <0.001 
Total cholesterol 204.3+13.73 193.9+23.58 <0.043 
 
Figure 18 
Mean Pattern of Lipid Parameters 
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Figure-19 
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The fasting lipid profile showed higher trends among patients 
with MA than patients without MA and reaching statistically significant 
levels. 
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Table 14 
Mean Pattern of SSS in presence of Microalbuminuria 
S.No 
Presenting 
factors 
Microalbuminuria 
P value Absent 
(n = 29) 
Present 
(n=31) 
1. Mean +SD 10.87+2.98 28.97+8.67 
<0.001 
2. 95% CI 14.31-21.96 21.66-24.54 
 Inference SSS is significantly decreased in the presence 
of Microalbuminuria with p<0.001 
 
Figure 20 
Mean Pattern of SSS in presence of 
Microalbuminuria
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The severity of stroke was assessed by Scandinavian Stroke Scale 
and was found to significantly lower in presence of microalbuminuria 
(8-19 with mean of 10.87+2.98) than without microalbuminuria (10-44 
with mean of 28.97+8.67). 
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Table 15 
 
Mean Pattern of Barthel Index in presence of Microalbuminuria 
 
S.No 
Presenting 
factors 
Microalbuminuria 
P value Absent 
(n = 29) 
Present 
(n=31) 
1. Mean +SD 56.29+5.77 67.48+10.91 <0.001 
  
Inference 
Barthel Index is significantly decreased in the 
presence of Microalbuminuria with p<0.001. 
 
Figure 21 
 
Mean Pattern of Barthel Index in presence of  
 Microalbuminuria 
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Assessment of activities of daily living by Barthel Index after 6 
weeks showed that it was lower in patients with microalbuminuria 
(50-70) than without microalbuminuria (45-100). 
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DISCUSSION 
The present study is a prospective study consisting of 60 recent 
ischemic stroke patients are divided into two categories as patients with 
microalbuminuria and patients without microalbuniuria. 
1. The incidence of microalbuminuria in recent ischemic stroke 
patients. 
2. The difference in laboratory parameters in patients with and 
without microalbuminuria. 
3. The  correlation  between  Scandinavian  Stroke  Scale  and  
Barthel  Index  and presence of microalbuminuria. 
Incidence of microalbuminuria 
       Pt with MA    Pt without MA 
Turaj et al 46.1% 13.5% 
Beamer et al 29% 10% 
Slowik A et al 46.7% 16.7% 
Present study 51.66% 48.34% 
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Our study found that among age and sex matched cases with 
microalbuminuria and without microalbuminuria are with similar 
predisposing factors, patients with new stroke were 6.32 times more 
likely to have microalbuminuria. The finding was similar to that of other 
studies including Turaj et al74, Beamer et al71 and Slowik A et al. 
Age and microalbuminuria 
 With MA Without MA 
Turaj et al 73.3+11.6 66.0+12.4 
Beamer et al 69+7 65+8 
Present study 47.19+14.03 48.69 +15.23 
 
The studies including Turaj et al74 and Beamer et al71 had 
found statistically significant correlation and attributed this to the 
phenomenon of older patients having a worse neurological deficit. 
Our study found correlation between age and presence of 
microalbuminuria but it didn’t reach statistically significant level. 
Gender and Microalbuminuria 
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 With MA Without MA 
Turaj et al 
Males 12 (50%) 14 (50%) 
Females 12 (50%) 14 (50%) 
Present study 
Males 20 (64.5%) 21 (72.4%) 
Females 10(33%) 8 (22.7%) 
The study did not reveal any difference in gender distribution 
between patients with or without microalbuminuria.  This was consistent 
with study by Turaj et al. 
Previous history of vascular events 
 With MA Without MA 
Turaj et al 9 (37.5%) 16 (57.2%) 
Present study 12 (16.12%) 2 (6.89%) 
Present study showed statistically significant increase in previous 
history of vascular events. But the study by Turaj et al74 did not 
find any difference between patients with and without 
microalbuminuria regarding previous history of vascular events. Our 
study is statistically significant. 
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Evidence of IHD and microalbuminuria 
 With MA Without MA 
Turaj et al 9 (37.5%) 15 (53.6%) 
Present study 8 (25.80%) 1 (3.44%) 
Turaj et al74 did not find any difference between patients with or 
without microalbuminuria in relation to presence of ischemic heart 
disease while our study found that the patients with microalbuminuria 
had greater evidence of IHD (25.80% Vs. 3.44%). This shows that 
microalbuminuria is related to all the atherosclerotic vascular events 
including IHD. 
Loss of consciousness and microalbuminuria 
 With MA Without MA p value 
Turaj et al 35.5% 14.3% < 0.05 
Present study 38.70% 6.89% 0.043 
Our study found statistically significant correlation between 
diminished consciousness between patients with and without 
microalbuminuria. The study by Turaj et al74 also had similar findings. 
Hence, presence of microalbuminuria was found to correlate with the 
severity of stroke. 
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SUMMARY 
1. The study population consisted of 60 recent ischemic stroke 
patients of age 48.69+15.20 years with 41 males (68.33%) and 19 
females (31.67%). 
2. The patients without microalbuminuria  included 29,  age and sex 
matched individuals. 
3. The patients with microalbuminuria  and without 
microalbuminuria  were matched for predisposing factors that 
included smoking and alcohol. 
4. Among the patients with microalbuminuria  , 15 (49.39%) had 
right hemiparesis, 16 (51.61%) had left hemi paresis. 
5. CT scan results revealed that middle cerebral artery infarct 
predominated the study population (right and left each 43.75%). 
6. The blood sugar levels were higher in with microalbuminuria  
(108.66+8.683) compared to without microalbuminuria  
(107.83+8.21) despite being in non-diabetic range but were not 
statistically significant. Other parameters like blood pressure, 
blood urea and serum creatinine were similar among the patients 
with microalbuminuria  and without microalbuminuria   
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7. In patients with recent ischemic stroke, 3 1 pts (51.65%) had 
microalbuminuria while 21 patients (49.35%) had no 
microalbuminuria.  
8. 12/31 patients with microalbuminuria (38.70) had altered 
consciousness while 2/29 patients without microalbuminuria 
(6.89) had altered consciousness. Hence microalbuminuria was 
found to be associated with more severe stroke. 
9. 8/31 patients with microalbuminuria (25.80) had ECG changes of 
ischemic heart disease while 1/29 (3.45%) patients without MA 
had IHD changes. Hence, microalbuminuria could be associated 
with not just stroke, but also other atherosclerotic vascular 
diseases. 
10. The mean age of patients with microalbuminuria was 
47.19+14.03 while that of patients without MA was 
48.69+15.23 years. T h e  difference was not  statistically 
significant level. 
11. In patients with microalbuminuria, total cholesterol was 
204+13.78, and triglycerides 192.45+35.59 while in patients 
without microalbuminuria, total cholesterol was 193.9+23.52,and 
triglycerides 157.93+33.49. The difference was statistically 
significant. 
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12. The Scandinavian Stroke Scale was low in patients with 
microalbuminuria (7.89-13.85) when compared to patients 
without microalbuminuria (20.30-14). Hence significant 
correlation was found between microalbuminuria and the 
severity of the neurological deficit. 
13. The Barthel index was low in patients with microalbuminuria (50-
70) when compared to patients without MA (45-100). Hence, 
there was significant correlation between microalbuminuria and 
poor stroke outcome. 
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CONCLUSION 
Various clinical studies have documented microalbuminuria as a 
risk factor for ischemic stroke. The present study found 
microalbuminuria in 51.66% of non-diabetic recent ischemic stroke 
patients and is  consistent  with  previous  studies  associating MA with 
atherosclerotic vascular disease. 
In the present study, We have shown that the measurement of 
microalbuminuria was found to be reliable predictor of stroke 
outcome 6 weeks after stroke. 
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ANNEXURE-1 
PROFORMA 
Name of the patient 
Age 
Sex 
IP No 
DOA 
DOD 
PRESENTING COMPLAINTS: 
 
Onset  
Mode 
Time 
March of events 
 Headache  
Vomiting 
State of consciousness 
Convulsions 
Speech disturbances 
Hemiparesis/Hemiplegia 
Hemianesthesia 
Bladder/bowel disturbances 
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Cranial nerve involvement 
Visual disturbances 
Unsteadiness of gait 
Giddiness 
PAST HISTORY 
Diabetes 
Hypertension 
TIA 
Previous CVA 
IHD 
Claudication 
Atrial fibrillation 
Tuberculosis 
TREATMENT HISTORY 
PERSONAL HISTORY 
Tobacco chewing 
Smoking 
Alcohol 
FAMILY HISTORY 
GENERAL PHYSICAL EXAMINATION 
Built 
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Nourishment 
Ht 
Wt 
BMI 
Vitals- pulse 
             BP 
             RR 
             Temperature 
SYSTEMIC EXAMINATION 
CENTRAL NERVOUS SYSTEM 
Handedness 
HMF 
   Level of consciousness 
   Appearance 
   Orientation 
   Memory 
   Intelligence 
  H allucination/Delusion 
  Speech 
Cranial nerves 
Motor system 
131 
  
       Nutrition 
       Tone 
       Power 
       Reflexus 
Sensory system 
      Touch 
      Temperature 
       Pain 
      Position sense 
      Vibration sensation 
      Cortical sensation 
     Rombergs sign 
Cerebellar signs 
Signs of meningeal irritation 
Other system 
   CVS 
   RS 
 ABDOMEN 
CLINICAL DIAGNOSIS 
INVESTIGATIONS 
    Complete blood count 
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    RBS 
    Blood urea/Sr.cratinine 
    ECG 
    Lipid profile 
    CT brain 
    LFT 
    Urine microalbuminuria by micral test 
FINAL DIAGNOSIS 
TREATMENT GIVEN 
FOLLOWUP DETAILS 
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INFORMED CONCENT 
DEPARTMENT OF GENERAL MEDICINE 
COIMBATORE MEDICAL COLLEGE,COIMBATORE 
Principle investigator:    Dr. M. Kavitha 
Research guide          :    Prof. Dr. C. MANOKARAN. M.D 
Organitation              :    Department of General medicine 
Informed consent       : I have been invited to participate in research 
project titled  
“A STUDY OF PROGNOSTIC SIGNIFICANCE OF 
MICROALBUMINURIA IN NONDIBETIC PATIENTS WITH 
RECENT ISCHEMIC CEREBROVASCULAR  STROKE” 
I understand it will answering a set of questionnaire, undergo physical 
examination, basic investigations and appropriate treatment. I also give 
consent to utilize my personal details for study purpose and can be 
contacted if necessary. I am aware that I have the right to withdraw at 
any time which will not affect  my medical care. 
Name of the patient; 
Signature: 
Date:   
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xg;g[jy;  gotk;; [ ; ;; [ ; ;; [ ; ; 
bgah; : 
ghypdk; :       taJ : 
Kfthp : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; kfg;ngW kUj;Jt 
Jiwapy; gl;l nkw;gog;g[ gapYk; khztp mth;fs; nkw;bfhs;Sk;  
"rh;f;fiu neha; my;yhj/ rkPgkhf \is ,uj;j ehs';fs; 
milg;ghy; ghjpf;fg;gl;lth;fspd; rpWePhpy; Ez; g[ujj;jpd; mst[ 
bfhz;L neha; Fzkhjypd; Kf;fpaj;Jtk;" Fwpj;j Ma;tpy; 
bra;Kiw kw;Wk; midj;J tptu';fisa[k; nfl;Lf; bfhz;L 
vdJ re;njf';fis bjspt[g;gLj;jpf; bfhz;nld; vd;gij 
bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;Jld;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; 
btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. ve;j neuj;jpy; ,e;j Ma;tpypUe;J ehd; tpyfpf; 
bfhs;s vdf;F chpik cz;L vd;gija[k; mwpntd;. 
 
,lk;  :      ifbahg;gk; / nuif 
ehs; : 
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KEY TO MASTER CHART 
 
MA -  microalbuminuria 
LFT -  liver function test 
RBS - random blood sugar 
TCL -  total cholesterol 
TGL - triglyceride 
PVE - previous vascular event 
SSS - scandinavian stroke scale 
BI -  Barthel index 
L -  left 
R - right 
M - male 
F - female 
IHD - ischemic heart disease 
 
 
S.No Name IP No. AGE SEX 
PRESENTING COMPLAINTS PAST HISTORY 
PRESENT 
HISTORY 
        
LIPID PROFILE                                   
BP 
      
W
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S
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S
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R
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T
C
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T
G
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S
B
P
 
D
B
P
 
C
T
 
B
R
A
I
N
 
M
A
 
S
S
S
 
B
I
 
1 RAJAN 10201 39 M R     - P             P 18 1.2 N 122 235 118 110 70 L P 8 50 
2 MUTHULAKSHMI 11231 41 F R     - P   P     P     28 0.8 N 128 230 255 110 70 L P 9 55 
3 VASANTHAPRIYAN 43541 19 M L     -             P P 34 1.1 N 100 200 182 116 72 R P 10 60 
4 BLAJI 44412 43 M L     -                 27 1.4 N 102 195 190 114 74 R P 8 55 
5 KANIMOZHI 23234 24 F L   P -                 29 1.7 N 95 155 200 110 72 R P 12 65 
6 SENKOTTAYAN 54586 45 M L   P -             P P 36 0.9 N 97 162 201 100 70 R P 16 60 
7 MURALI 57301 27 M L     -               P 44 0.9 N 99 175 165 132 82 R P 18 65 
8 MOIDEEN 50501 47 M R   P -     P     P P P 35 1.4 N 102 182 117 130 84 R P 19 70 
9 JAMES 10586 51 M R     -                 37 1.3 N 126 193 112 100 74 L P 10 55 
10 MARIYAMMAL 10593 53 F R   P -                 26 1.6 N 120 197 205 126 80 L P 12 55 
11 PALANISAMY 11731 62 M L   P -     P     P P P 36 1.3 N 111 205 223 124 80 R P 10 50 
12 PODUM PONNU 11926 65 F L   P -     P           27 1.4 N 115 225 215 130 82 R P 8 50 
13 ARIVAZHAGAN 11954 53 M L     -     P     P P P 29 1.2 N 87 225 219 126 84 R P 17 65 
14 MUSTHAFA 40526 55 M R     - P           P P 30 1.3 N 95 196 216 124 74 L P 8 50 
15 GEETHA 31264 64 F R   P - P   P     P     20 1.3 N 96 187 225 124 76 L P 9 55 
16 ELANGO 35352 29 M L     -               P 38 1.4 N 117 147 127 120 70 L P 10 60 
17 PETCHIYAMML 50123 49 F R     -                 29 1.5 N 118 165 155 110 84 L P 11 55 
18 NATARAJAN 45621 57 M L   P -     P     P P P 37 1.2 N 117 167 167 110 70 R P 12 60 
19 NANDHAKUMAR 57281 30 M L     -     P       P P 35 1.2 N 122 171 165 130 78 R P 10 55 
20 SELVI 9545 59 F R   P - P P P     P     39 0.9 N 126 179 200 130 84 L P 9 55 
21 MARIMUTHU 10643 50 M L     -             P P 40 0.8 N 115 205 208 128 70 R P 8 50 
22 MUNIYAMMAL 12191 40 F R     -           P     27 1.4 N 97 223 209 120 70 R P 9 50 
23 RAJASEKARAN 20243 52 M R     - P             P 38 0.6 N 87 202 225 110 70 L P 10 60 
24 RATHNAM 56573 32 M R     -     P       P P 33 0.9 N 95 204 215 110 68 L P 11 60 
25 KARTHIKEYAN 55551 35 M L     -               P 21 1.2 N 112 215 216 114 80 R P 13 60 
26 MURUGAN 57891 51 M L   P -                 29 1.4 N 119 219 217 100 70 R P 12 65 
27 VISALATCHI 44561 54 F L     -               P 25 1.3 N 78 211 219 110 72 R P 8 50 
28 VIRUMANDI 44563 58 M L     -     P         P 29 1.2 N 95 159 195 110 74 R P 10 50 
29 SENBAGAVALLI 38492 77 F R   P - P   P           66 1.3 N 116 187 198 110 74 L P 11 55 
30 SUBRAYAN 39415 69 M R   P -             P P 34 1.3 N 119 190 197 120 78 L P 11 50 
31 SARASWATHI 38145 33 F R     -             P P 29 1.3 N 124 205 210 130 80 L P 8 50 
32 KARUPPAYAH 40561 42 M R       P           P   28 1.2 N 98 200 198 110 70 L - 30 70 
33 ARUKKANI 47245 51 F L                       24 1.4 N 95 215 150 114 72 R - 32 75 
34 JEGADEESAN 46489 21 M L                       45 0.9 N 110 217 160 122 72 R - 35 70 
35 SHANTHANAM 50676 40 M R                       44 0.8 N 115 198 202 130 70 L - 31 70 
36 DAVID 50129 35 M L                   P P 46 0.9 N 120 187 216 110 70 R - 26 65 
37 MAHENDIRAN 42819 25 M R                   P   23 1.3 N 112 210 195 100 70 L - 28 60 
38 PRABHAKARAN 62048 51 M R       P           P   24 1.4 N 125 210 145 102 72 L - 44 100 
39 MAYILSAMY 49955 65 M L                       35 1.2 N 92 196 175 110 74 R - 35 70 
40 LATHA 45214 69 F L                       33 1.3 N 80 225 185 120 80 R - 30 70 
41 NARAYANAN 44616 45 M R       P           P P 65 1.2 N 110 150 98 130 82 L - 26 65 
42 KATHIRVEL 32814 68 M L       P P P       P   44 1.3 N 114 146 125 132 80 R - 28 60 
43 CHELLADURAI 21119 53 M R                       34 1.3 N 92 210 200 139 80 L - 28 60 
44 RAJAJI 21189 65 M L                       28 1.4 N 98 213 198 124 80 R - 29 65 
45 RAKKU 51004 47 F R       P               29 1.5 N 100 190 200 122 82 L - 15 60 
46 SIVANANDI 45555 83 M L P P               P   26 1.3 N 114 185 205 120 84 R - 12 50 
47 MARIYAPPAN 45819 28 M R                       27 0.9 N 115 170 140 110 80 L - 25 57 
48 ARAYEE 43108 54 F L                       28 1.3 N 113 175 130 112 70 R - 26 60 
49 SUBRAMANIYAN 53916 36 M R                   P P 25 0.8 N 103 190 140 110 70 L - 13 50 
50 KUPPAMMAL 57819 59 F B/L                       22 0.9 N 118 210 150 100 70 CL - 10 45 
51 SEVALAI 52312 29 M L                   P P 21 0.7 N 94 225 155 122 72 R - 30 70 
52 POONKODI 63016 56 F L   P                   29 0.9 N 95 204 150 130 74 R - 42 80 
53 SUNDHAR 57192 62 M L       P         P P   28 0.9 N 96 208 135 136 76 R - 41 80 
54 VIJAYAKUMAR 48912 39 M R           P           24 1.3 N 114 225 120 110 70 L - 40 80 
55 THIRUMAL 48197 26 M L                     P 33 1.4 N 125 224 110 110 70 R - 39 80 
56 SARANYA 33121 54 F R                       36 1.2 N 120 210 112 120 82 L - 38 70 
57 SIKENDAR 34532 48 M R P                     44 1.3 N 118 188 120 122 80 L - 25 65 
58 DHANALAKSHMI 40011 54 F L                       22 1.3 N 116 114 150 110 70 R - 28 70 
59 MAHALINGAM 47111 42 M R       P               25 1.3 N 114 196 144 114 72 L - 28 70 
60 MUTHUMARI 49122 65 M R       P               23 1.2 N 106 192 172 116 74 L - 26 70 
 
